LONDON (MarketWatch) -- Lung-disease patients taking GlaxoSmithKline PLC's GSK asthma inhaler Seretide have better survival benefits than those taking a rival product, according to a study published ...
This study has demonstrated that doubling the dose of Seretide™ administered via the Diskus™ inhaler over a short period is safe and well tolerated. Whilst this is not a recommended treatment approach ...
Mylan becomes the first company to market a generic version of the UK's number one prescribed long-acting beta2-agonist + inhaled corticosteroid pressurized metered-dose inhaler asthma therapy[1],[2] ...
LONDON, July 9 (Reuters) - GlaxoSmithKline Plc has won a licence extension in Europe for Seretide, allowing its top-selling inhaler product to be used in a wider population of patients with the lung ...
Ex-al Qaida member claims Israel-Lebanon ceasefire actually about Iran ...
Vectura Group said on Friday a British court had ruled in its and partner Sandoz's favour over the packaging of a generic version of an inhaler made by bigger rival GlaxoSmithKline. Vectura said the ...
(Reuters) - GlaxoSmithKline Plc said on Wednesday the U.S health regulator approved its lung disease drug Trelegy Ellipta for expanded use, making it the first inhaler delivering three drugs at once ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results